Literature DB >> 18550653

Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients.

Kevin L Winthrop1, Melissa Nyendak, Helene Calvet, Peter Oh, Melanie Lo, Gwendolyn Swarbrick, Carol Johnson, Deborah A Lewinsohn, David M Lewinsohn, Gerald H Mazurek.   

Abstract

BACKGROUND AND OBJECTIVES: End-stage renal disease (ESRD) patients are at high risk for tuberculosis (TB). IFN-gamma release assays that assess immune responses to specific TB antigens offer potential advantages over tuberculin skin testing (TST) in screening such patients for Mycobacterium tuberculosis infection. This study sought to determine whether IFN-gamma release assay results are more closely associated with recent TB exposure than TST results. DESIGN, SETTING, PARTICIPANTS, AND MEASURES: Prospective cohort investigation of patients at a hemodialysis center with a smear-positive case of TB. Patients without a history of TB underwent initial and repeat testing with TST, and with the IFN-gamma assays QuantiFERON-TB Gold (QFT-G) and ELISPOT test. Outcome measures included the prevalence of positive test results, identification of factors associated with positive results, and test result discordance.
RESULTS: A total of 100 (47% foreign born; median age, 55 yr; age range, 18 to 83 yr) of 124 eligible patients were enrolled. Twenty-six persons had positive TST results, 21 had positive QFT-G results, and 27 had positive ELISPOT results. Patients with TB case contact were likely to have a positive QFT-G result (P = 0.02) and ELISPOT results (P = 0.04), whereas TB case contact was not associated with positive TST results (P = 0.7). Positive TST results were associated with foreign birth (P = 0.04) and having had a TST in the previous year (P = 0.04).
CONCLUSIONS: Positive IFN-gamma assay results were more closely associated with recent TB exposure than were positive TST results. QFT-G and ELISPOT might offer a better method for detecting TB infection in ESRD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550653      PMCID: PMC2518786          DOI: 10.2215/CJN.01010208

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  20 in total

1.  Impaired cellular immune function in patients with end-stage renal failure.

Authors:  M Girndt; U Sester; M Sester; H Kaul; H Köhler
Journal:  Nephrol Dial Transplant       Date:  1999-12       Impact factor: 5.992

2.  Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection.

Authors:  Homayoun Shams; Stephen E Weis; Peter Klucar; Ajit Lalvani; Patrick K Moonan; Janice M Pogoda; Katie Ewer; Peter F Barnes
Journal:  Am J Respir Crit Care Med       Date:  2005-08-04       Impact factor: 21.405

3.  Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis.

Authors:  P D Johnson; R L Stuart; M L Grayson; D Olden; A Clancy; P Ravn; P Andersen; W J Britton; J S Rothel
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size?

Authors:  F Tissot; G Zanetti; P Francioli; J-P Zellweger; F Zysset
Journal:  Clin Infect Dis       Date:  2004-12-20       Impact factor: 9.079

5.  Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity.

Authors:  D M Lewinsohn; L Zhu; V J Madison; D C Dillon; S P Fling; S G Reed; K H Grabstein; M R Alderson
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

6.  Ten years' survey of dialysis-associated tuberculosis.

Authors:  S Sasaki; T Akiba; M Suenaga; S Tomura; N Yoshiyama; S Nakagawa; T Shoji; T Sasaoka; J Takeuchi
Journal:  Nephron       Date:  1979       Impact factor: 2.847

7.  Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis.

Authors:  Gerald H Mazurek; Stephen E Weis; Patrick K Moonan; Charles L Daley; John Bernardo; Alfred A Lardizabal; Randall R Reves; Sean R Toney; Laura J Daniels; Philip A LoBue
Journal:  Clin Infect Dis       Date:  2007-08-24       Impact factor: 9.079

8.  Tuberculosis in patients with end-stage renal disease.

Authors:  O T Andrew; P Y Schoenfeld; P C Hopewell; M H Humphreys
Journal:  Am J Med       Date:  1980-01       Impact factor: 4.965

9.  Early diagnosis of subclinical multidrug-resistant tuberculosis.

Authors:  Luca Richeldi; Katie Ewer; Monica Losi; David M Hansell; Pietro Roversi; Leonardo M Fabbri; Ajit Lalvani
Journal:  Ann Intern Med       Date:  2004-05-04       Impact factor: 25.391

10.  Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel.

Authors:  Laura Passalent; Kamran Khan; Robert Richardson; Jun Wang; Helen Dedier; Michael Gardam
Journal:  Clin J Am Soc Nephrol       Date:  2006-10-18       Impact factor: 8.237

View more
  16 in total

1.  High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test.

Authors:  Susan Shin-Jung Lee; Kang-Ju Chou; Horng-Yunn Dou; Tsi-Shu Huang; Yen-Yun Ni; Hua-Chang Fang; Hung-Chin Tsai; Cheng-Len Sy; Jui-Kuang Chen; Kuang-Sheng Wu; Yung-Hsin Wang; Hsi-Hsun Lin; Yao-Shen Chen
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  Interferon-gamma release assays are a better tuberculosis screening test for hemodialysis patients: A study and review of the literature.

Authors:  J Grant; J Jastrzebski; J Johnston; A Stefanovic; J Jastrabesky; K Elwood; D Roscoe; R Balshaw; E Bryce
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

3.  Infections in hemodialysis: a concise review - Part 1: bacteremia and respiratory infections.

Authors:  T Eleftheriadis; V Liakopoulos; K Leivaditis; G Antoniadi; I Stefanidis
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

Review 4.  When kidneys and lungs suffer together.

Authors:  Claudio Sorino; Nicola Scichilone; Claudio Pedone; Stefano Negri; Dina Visca; Antonio Spanevello
Journal:  J Nephrol       Date:  2018-12-06       Impact factor: 3.902

Review 5.  Urinary tuberculosis: modern issues.

Authors:  Gilbert J Wise
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

6.  Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests.

Authors:  Richard D Powell; William C Whitworth; John Bernardo; Patrick K Moonan; Gerald H Mazurek
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

7.  Comparison of interferon gamma release assay & tuberculin skin tests for diagnosis of latent tuberculosis in patients on maintenance haemodialysis.

Authors:  Sanjay K Agarwal; Urvashi B Singh; Sabahat H Zaidi; Sanjay Gupta; Ravinder M Pandey
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

8.  Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to M. tuberculosis.

Authors:  Luis Anibarro; Matilde Trigo; Diana Feijoó; Mónica Ríos; Luisa Palomares; Alberto Pena; Marta Núñez; Carlos Villaverde; África González-Fernández
Journal:  BMC Infect Dis       Date:  2012-08-20       Impact factor: 3.090

9.  A multicenter clinical evaluation of Mycobacterium tuberculosis IgG/IgM antibody detection using the colloidal gold method.

Authors:  Y Wang; B Lu; J Liu; T Xiao; K Wan; C Guan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-10       Impact factor: 3.267

10.  Heparin-binding haemagglutinin, a new tool for the detection of latent Mycobacterium tuberculosis infection in hemodialysis patients.

Authors:  Rodrigue Dessein; Véronique Corbière; Joëlle Nortier; Max Dratwa; Karine Gastaldello; Agnieszka Pozdzik; Sophie Lecher; Bruno Grandbastien; Camille Locht; Françoise Mascart
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.